|
1
|
Tao Z, Shi A, Lu C, Song T, Zhang Z and
Zhao J: Breast cancer: Epidemiology and Etiology. Cell Biochem
Biophys. 72:333–338. 2015. View Article : Google Scholar
|
|
2
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hynes NE and MacDonald G: ErbB receptors
and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J,
Chen D, Gu J, He X and Huang S: Circular RNA is enriched and stable
in exosomes: A promising biomarker for cancer diagnosis. Cell Res.
25:981–984. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salzman J: Circular RNA expression: Its
potential regulation and function. Trends Genet. 32:309–316. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sekar S and Liang WS: Circular RNA
expression and function in the brain. Noncoding RNA Res. 4:23–29.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou Z, Sun B, Huang S and Zhao L: Roles
of circular RNAs in immune regulation and autoimmune diseases. Cell
Death Dis. 10:5032019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Greene J, Baird AM, Brady L, Lim M, Gray
SG, McDermott R and Finn SP: Circular RNAs: Biogenesis, function
and role in human diseases. Front Mol Biosci. 4:382017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han B, Chao J and Yao H: Circular RNA and
its mechanisms in disease: From the bench to the clinic. Pharmacol
Ther. 187:31–44. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lasda E and Parker R: Circular RNAs:
Diversity of form and function. RNA. 20:1829–1842. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hansen TB, Jensen TI, Clausen BH, Bramsen
JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function
as efficient microRNA sponges. Nature. 495:384–388. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Panda AC: Circular RNAs act as miRNA
sponges. Adv Exp Med Biol. 1087:67–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong
F, Ren D, Ye X, Li C, Wang Y, et al: Circular RNAs function as
ceRNAs to regulate and control human cancer progression. Mol
Cancer. 17:792018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding L and Zhang H: Circ-ATP8A2 promotes
cell proliferation and invasion as a ceRNA to target EGFR by
sponging miR-433 in cervical cancer. Gene. 705:103–108. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun H, Xi P, Sun Z, Wang Q, Zhu B, Zhou J,
Jin H, Zheng W, Tang W, Cao H and Cao X: Circ-SFMBT2 promotes the
proliferation of gastric cancer cells through sponging miR-182-5p
to enhance CREB1 expression. Cancer Manag Res. 10:5725–5734. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ghaemi Z, Soltani BM and Mowla SJ:
MicroRNA-326 functions as a tumor suppressor in breast cancer by
targeting ErbB/PI3K signaling pathway. Front Oncol. 9:6532019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanai F, Marignani PA, Sarbassova D, Yagi
R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC
and Yaffe MB: TAZ: A novel transcriptional co-activator regulated
by interactions with 14-3-3 and PDZ domain proteins. EMBO J.
19:6778–6791. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mahoney WM Jr, Hong JH, Yaffe MB and
Farrance IK: The transcriptional co-activator TAZ interacts
differentially with transcriptional enhancer factor-1 (TEF-1)
family members. Biochem J. 388:217–225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Murakami M, Tominaga J, Makita R, Uchijima
Y, Kurihara Y, Nakagawa O, Asano T and Kurihara H: Transcriptional
activity of Pax3 is co-activated by TAZ. Biochem Biophys Res
Commun. 339:533–539. 2006. View Article : Google Scholar
|
|
22
|
Chan SW, Lim CJ, Guo K, Ng CP, Lee I,
Hunziker W, Zeng Q and Hong W: A role for TAZ in migration,
invasion, and tumorigenesis of breast cancer cells. Cancer Res.
68:2592–2598. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
24
|
Shi F, Shi Z, Zhao Y and Tian J: CircRNA
hsa-circ-0014359 promotes glioma progression by regulating
miR-153/PI3K signaling. Biochem Biophys Res Commun. 510:614–620.
2019. View Article : Google Scholar
|
|
25
|
Wan J, Hao L, Zheng X and Li Z: Circular
RNA circ_0020123 promotes non-small cell lung cancer progression by
acting as a ceRNA for miR-488-3p to regulate ADAM9 expression.
Biochem Biophys Res Commun. 515:303–309. 2019. View Article : Google Scholar
|
|
26
|
Xu JZ, Shao CC, Wang XJ, Zhao X, Chen JQ,
Ouyang YX, Feng J, Zhang F, Huang WH, Ying Q, et al: circTADA2As
suppress breast cancer progression and metastasis via targeting
miR-203a-3p/SOCS3 axis. Cell Death Dis. 10:1752019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li C, Tian Y, Liang Y and Li Q:
Circ_0008035 contributes to cell proliferation and inhibits
apoptosis and ferroptosis in gastric cancer via miR-599/EIF4A1
axis. Cancer Cell Int. 20:842020. View Article : Google Scholar :
|
|
28
|
Qu Y, Zhu J, Liu J and Qi L: Circular RNA
circ_0079593 indicates a poor prognosis and facilitates cell growth
and invasion by sponging miR-182 and miR-433 in glioma. J Cell
Biochem. 120:18005–18013. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ji S, Zhang B, Kong Y, Ma F and Hua Y:
miR-326 Inhibits Gastric Cancer Cell Growth Through Downregulating
NOB1. Oncology Pesearch. 25:853–861. 2017.
|
|
30
|
Liang X, Li Z, Men Q, Li Y, Li H and Chong
T: miR-326 functions as a tumor suppressor in human prostatic
carcinoma by targeting Mucin1. Biomed Pharmacother. 108:574–583.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nguyen CDK and Yi C: YAP/TAZ signaling and
resistance to cancer therapy. Trends Cancer. 5:283–296. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Warren JSA, Xiao Y and Lamar JM: YAP/TAZ
activation as a target for treating metastatic cancer. Cancers
(Basel). 10:1152018. View Article : Google Scholar
|
|
35
|
Zanconato F, Battilana G, Cordenonsi M and
Piccolo S: YAP/TAZ as therapeutic targets in cancer. Curr Opin
Pharmacol. 29:26–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi P, Feng J and Chen C: Hippo pathway in
mammary gland development and breast cancer. Acta Biochim Biophys
Sin (Shanghai). 47:53–59. 2015. View Article : Google Scholar
|
